JP2019532997A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019532997A5 JP2019532997A5 JP2019523665A JP2019523665A JP2019532997A5 JP 2019532997 A5 JP2019532997 A5 JP 2019532997A5 JP 2019523665 A JP2019523665 A JP 2019523665A JP 2019523665 A JP2019523665 A JP 2019523665A JP 2019532997 A5 JP2019532997 A5 JP 2019532997A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- inhibitor
- subject
- administration
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000004027 cell Anatomy 0.000 claims 101
- 210000001744 T-lymphocyte Anatomy 0.000 claims 93
- 239000003112 inhibitor Substances 0.000 claims 74
- 206010028980 Neoplasm Diseases 0.000 claims 62
- 239000000427 antigen Substances 0.000 claims 57
- 108091007433 antigens Proteins 0.000 claims 57
- 102000036639 antigens Human genes 0.000 claims 57
- 201000011510 cancer Diseases 0.000 claims 57
- 239000003814 drug Substances 0.000 claims 42
- 238000011282 treatment Methods 0.000 claims 38
- 102000042834 TEC family Human genes 0.000 claims 37
- 108091082333 TEC family Proteins 0.000 claims 37
- 239000000203 mixture Substances 0.000 claims 33
- 238000002560 therapeutic procedure Methods 0.000 claims 31
- 102000005962 receptors Human genes 0.000 claims 27
- 108020003175 receptors Proteins 0.000 claims 27
- 230000035772 mutation Effects 0.000 claims 25
- 229940124291 BTK inhibitor Drugs 0.000 claims 23
- 230000000977 initiatory effect Effects 0.000 claims 20
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 claims 18
- 102100029823 Tyrosine-protein kinase BTK Human genes 0.000 claims 18
- 102000039446 nucleic acids Human genes 0.000 claims 16
- 108020004707 nucleic acids Proteins 0.000 claims 16
- 150000007523 nucleic acids Chemical class 0.000 claims 16
- 229940079593 drug Drugs 0.000 claims 15
- 230000005764 inhibitory process Effects 0.000 claims 15
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 13
- -1 L1-CAM Proteins 0.000 claims 13
- 210000003719 b-lymphocyte Anatomy 0.000 claims 13
- 230000004044 response Effects 0.000 claims 13
- 238000002659 cell therapy Methods 0.000 claims 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 12
- 102000004422 Phospholipase C gamma Human genes 0.000 claims 11
- 108010056751 Phospholipase C gamma Proteins 0.000 claims 11
- 210000004369 blood Anatomy 0.000 claims 11
- 239000008280 blood Substances 0.000 claims 11
- 229940043355 kinase inhibitor Drugs 0.000 claims 10
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 10
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 9
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 9
- 230000037396 body weight Effects 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 6
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 6
- 230000001605 fetal effect Effects 0.000 claims 6
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 6
- 229960001507 ibrutinib Drugs 0.000 claims 6
- 238000006467 substitution reaction Methods 0.000 claims 6
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 5
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 5
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 5
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 5
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 5
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 5
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 5
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 5
- 108091008874 T cell receptors Proteins 0.000 claims 5
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 5
- 210000004698 lymphocyte Anatomy 0.000 claims 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 5
- 108010058905 CD44v6 antigen Proteins 0.000 claims 4
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 4
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 4
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims 4
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 4
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 4
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 4
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims 4
- 102000003735 Mesothelin Human genes 0.000 claims 4
- 108090000015 Mesothelin Proteins 0.000 claims 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 4
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims 4
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 4
- 208000008383 Wilms tumor Diseases 0.000 claims 4
- 208000026448 Wilms tumor 1 Diseases 0.000 claims 4
- 102100022748 Wilms tumor protein Human genes 0.000 claims 4
- 101710127857 Wilms tumor protein Proteins 0.000 claims 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 101150047061 tag-72 gene Proteins 0.000 claims 4
- 208000031404 Chromosome Aberrations Diseases 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 108700010039 chimeric receptor Proteins 0.000 claims 3
- 238000002648 combination therapy Methods 0.000 claims 3
- 229960004397 cyclophosphamide Drugs 0.000 claims 3
- 229960000390 fludarabine Drugs 0.000 claims 3
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 3
- 230000036210 malignancy Effects 0.000 claims 3
- 208000037821 progressive disease Diseases 0.000 claims 3
- 230000007781 signaling event Effects 0.000 claims 3
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 2
- 102100032912 CD44 antigen Human genes 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 102000016736 Cyclin Human genes 0.000 claims 2
- 108050006400 Cyclin Proteins 0.000 claims 2
- 108010060273 Cyclin A2 Proteins 0.000 claims 2
- 102100025191 Cyclin-A2 Human genes 0.000 claims 2
- 101150029707 ERBB2 gene Proteins 0.000 claims 2
- 102100038595 Estrogen receptor Human genes 0.000 claims 2
- 101150032879 Fcrl5 gene Proteins 0.000 claims 2
- 108091006027 G proteins Proteins 0.000 claims 2
- 102000030782 GTP binding Human genes 0.000 claims 2
- 108091000058 GTP-Binding Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101100165850 Homo sapiens CA9 gene Proteins 0.000 claims 2
- 101100166600 Homo sapiens CD28 gene Proteins 0.000 claims 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 2
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 2
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims 2
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 2
- 102000004559 Interleukin-13 Receptors Human genes 0.000 claims 2
- 108010017511 Interleukin-13 Receptors Proteins 0.000 claims 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 102100022430 Melanocyte protein PMEL Human genes 0.000 claims 2
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 102100023123 Mucin-16 Human genes 0.000 claims 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims 2
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 2
- 108060006580 PRAME Proteins 0.000 claims 2
- 102000036673 PRAME Human genes 0.000 claims 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 claims 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 2
- 101800001271 Surface protein Proteins 0.000 claims 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000003432 anti-folate effect Effects 0.000 claims 2
- 229940127074 antifolate Drugs 0.000 claims 2
- 239000000539 dimer Substances 0.000 claims 2
- 230000009977 dual effect Effects 0.000 claims 2
- 108010038795 estrogen receptors Proteins 0.000 claims 2
- 229960000304 folic acid Drugs 0.000 claims 2
- 235000019152 folic acid Nutrition 0.000 claims 2
- 239000011724 folic acid Substances 0.000 claims 2
- 239000004052 folic acid antagonist Substances 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 102000006495 integrins Human genes 0.000 claims 2
- 108010044426 integrins Proteins 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 210000004986 primary T-cell Anatomy 0.000 claims 2
- 102000003998 progesterone receptors Human genes 0.000 claims 2
- 108090000468 progesterone receptors Proteins 0.000 claims 2
- 230000011664 signaling Effects 0.000 claims 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 1
- 206010067477 Cytogenetic abnormality Diseases 0.000 claims 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 102220536388 Probable helicase with zinc finger domain_C48R_mutation Human genes 0.000 claims 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 claims 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 1
- 229960004373 acetylcholine Drugs 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 208000014619 adult acute lymphoblastic leukemia Diseases 0.000 claims 1
- 201000011184 adult acute lymphocytic leukemia Diseases 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 238000011284 combination treatment Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000018109 developmental process Effects 0.000 claims 1
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 238000000099 in vitro assay Methods 0.000 claims 1
- 230000004068 intracellular signaling Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 230000007774 longterm Effects 0.000 claims 1
- 208000003747 lymphoid leukemia Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 244000052769 pathogen Species 0.000 claims 1
- 230000002688 persistence Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 230000002250 progressing effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 230000009261 transgenic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023103197A JP2023120386A (ja) | 2016-11-03 | 2023-06-23 | Ｔ細胞療法とｂｔｋ阻害剤との併用療法 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662417312P | 2016-11-03 | 2016-11-03 | |
| US62/417,312 | 2016-11-03 | ||
| US201662429735P | 2016-12-03 | 2016-12-03 | |
| US62/429,735 | 2016-12-03 | ||
| US201762574706P | 2017-10-19 | 2017-10-19 | |
| US62/574,706 | 2017-10-19 | ||
| PCT/US2017/060060 WO2018085731A2 (en) | 2016-11-03 | 2017-11-03 | Combination therapy of a t cell therapy and a btk inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023103197A Division JP2023120386A (ja) | 2016-11-03 | 2023-06-23 | Ｔ細胞療法とｂｔｋ阻害剤との併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019532997A JP2019532997A (ja) | 2019-11-14 |
| JP2019532997A5 true JP2019532997A5 (OSRAM) | 2020-12-17 |
Family
ID=60515805
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523665A Withdrawn JP2019532997A (ja) | 2016-11-03 | 2017-11-03 | Ｔ細胞療法とｂｔｋ阻害剤との併用療法 |
| JP2023103197A Pending JP2023120386A (ja) | 2016-11-03 | 2023-06-23 | Ｔ細胞療法とｂｔｋ阻害剤との併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023103197A Pending JP2023120386A (ja) | 2016-11-03 | 2023-06-23 | Ｔ細胞療法とｂｔｋ阻害剤との併用療法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20190298772A1 (OSRAM) |
| EP (1) | EP3534938A2 (OSRAM) |
| JP (2) | JP2019532997A (OSRAM) |
| CN (1) | CN110139669A (OSRAM) |
| AU (1) | AU2017355544A1 (OSRAM) |
| CA (1) | CA3042049A1 (OSRAM) |
| MA (1) | MA46783A (OSRAM) |
| MX (2) | MX2019005029A (OSRAM) |
| WO (1) | WO2018085731A2 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2020511462A (ja) | 2016-12-03 | 2020-04-16 | ジュノー セラピューティクス インコーポレイテッド | キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物 |
| PT3618842T (pt) * | 2017-05-01 | 2024-01-12 | Juno Therapeutics Inc | Combinação de uma terapia celular e de um composto imunomodulador |
| MX2019014268A (es) | 2017-06-02 | 2020-08-03 | Juno Therapeutics Inc | Artículos de manufactura y métodos para tratamiento usando terapia celular adoptiva. |
| PL3703750T3 (pl) | 2017-11-01 | 2025-04-07 | Juno Therapeutics, Inc. | Chimeryczne receptory antygenowe specyficzne dla antygenu dojrzewania komórek b i kodujące polinukleotydy |
| WO2019089982A1 (en) | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
| BR112020018658A2 (pt) | 2018-03-15 | 2020-12-29 | KSQ Therapeutics, Inc. | Composições de regulação gênica e métodos para imu-noterapia aprimorada |
| US12263190B2 (en) | 2018-11-08 | 2025-04-01 | Juno Therapeutics, Inc. | Methods and combinations for treatment and T cell modulation |
| US20230158071A1 (en) * | 2018-12-07 | 2023-05-25 | Crage Medical Co., Limited | Tumor combined immunotherapy |
| JP7725446B2 (ja) * | 2019-07-26 | 2025-08-19 | ユハン コーポレーション | 抗ｈｅｒ２／抗４－１ｂｂ二重特異性抗体及びその使用 |
| KR20220131892A (ko) | 2019-11-05 | 2022-09-29 | 주노 쎄러퓨티크스 인코퍼레이티드 | 치료용 ｔ 세포 조성물의 속성 결정 방법 |
| US20230138309A1 (en) * | 2020-03-20 | 2023-05-04 | The United States Of America,As Represented By The Secretary,Department Of Health And Human Services | Methods of isolating t-cells and t-cell receptors from tumor by single-cell analysis for immunotherapy |
| CN115803824A (zh) | 2020-05-13 | 2023-03-14 | 朱诺治疗学股份有限公司 | 鉴定与临床反应相关的特征的方法及其用途 |
| WO2023278424A1 (en) * | 2021-06-28 | 2023-01-05 | The Regents Of The University Of California | Methods for treating and ameliorating t cell related diseases |
| WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
| WO2025137059A1 (en) * | 2023-12-18 | 2025-06-26 | Corvus Pharmaceuticals, Inc. | Use of itk inhibitors and car t-cell therapy |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| WO1990007380A2 (en) | 1988-12-28 | 1990-07-12 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| WO1996013593A2 (en) | 1994-10-26 | 1996-05-09 | Procept, Inc. | Soluble single chain t cell receptors |
| WO1996018105A1 (en) | 1994-12-06 | 1996-06-13 | The President And Fellows Of Harvard College | Single chain t-cell receptor |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| US6451995B1 (en) | 1996-03-20 | 2002-09-17 | Sloan-Kettering Institute For Cancer Research | Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods |
| ATE533784T1 (de) | 1997-10-02 | 2011-12-15 | Altor Bioscience Corp | Lösliche, einzelkettige proteine des t- zellrezeptors |
| WO1999060120A2 (en) | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| WO2000014257A1 (en) | 1998-09-04 | 2000-03-16 | Sloan-Kettering Institute For Cancer Research | Fusion receptors specific for prostate-specific membrane antigen and uses thereof |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| WO2001094944A2 (en) | 2000-06-02 | 2001-12-13 | Memorial Sloan-Kettering Cancer Center | Artificial antigen presenting cells and methods of use thereof |
| JP5312721B2 (ja) | 2000-11-07 | 2013-10-09 | シティ・オブ・ホープ | Ｃｄ１９特異的再指向免疫細胞 |
| AU3113902A (en) | 2000-12-21 | 2002-07-01 | Bristol Myers Squibb Co | Thiazolyl inhibitors of tec family tyrosine kinases |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| DE60203125T2 (de) | 2001-08-31 | 2006-04-06 | Avidex Ltd., Abingdon | Löslicher t zell rezeptor |
| US7939059B2 (en) | 2001-12-10 | 2011-05-10 | California Institute Of Technology | Method for the generation of antigen-specific lymphocytes |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| SE0202429D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel Compounds |
| SE0202461D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| SE0202462D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel use |
| SE0202463D0 (sv) | 2002-08-14 | 2002-08-14 | Astrazeneca Ab | Novel compounds |
| WO2004033685A1 (en) | 2002-10-09 | 2004-04-22 | Avidex Ltd | Single chain recombinant t cell receptors |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| NZ545421A (en) | 2003-09-08 | 2010-03-26 | Aventis Pharma Inc | Thienopyrazoles |
| US20050176792A1 (en) | 2004-01-14 | 2005-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | Ketone substituted benzimidazole compounds |
| US20050209284A1 (en) | 2004-02-12 | 2005-09-22 | Boehringer Ingelheim Pharmaceuticals, Inc. | Tec kinase inhibitors |
| DE602005022595D1 (de) | 2004-06-29 | 2010-09-09 | Immunocore Ltd | Einen modifizierten t-zellen-rezeptor exprimierende zellen |
| RU2423351C2 (ru) | 2004-12-16 | 2011-07-10 | Вертекс Фармасьютикалз Инкорпорейтед | Пирид-2-оны, применимые как ингибиторы протеинкиназ семейства тес для лечения воспалительных, пролиферативных и иммунологически-опосредованных заболеваний |
| WO2007016977A1 (de) | 2005-08-05 | 2007-02-15 | Delica Ag | Vorrichtung zum extrahieren eines in einer kapsel enthaltenen extraktionsgutes mit einem flüssigen extraktionsmittel |
| ATE548363T1 (de) | 2005-08-29 | 2012-03-15 | Vertex Pharma | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen |
| WO2007058832A2 (en) | 2005-11-12 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Pyrrolo (2, 3-b) pyridine derivatives useful as tec kinase inhibitors |
| WO2007076228A2 (en) | 2005-12-20 | 2007-07-05 | Boehringer Ingelheim International Gmbh | 2-(ih-thieno [3,2-c] pyrazol-3yl)-ih-indole derivatives and related compounds as tec kinase inhibitors for the treatment of inflammations and immunological disorders |
| JP5682051B2 (ja) | 2006-05-18 | 2015-03-11 | ファーマサイクリックス，インク． | 細胞内キナーゼ阻害剤 |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| WO2008025821A1 (en) | 2006-08-30 | 2008-03-06 | Cellzome Limited | Triazole derivatives as kinase inhibitors |
| EP1900727A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Aminopyridine derivatives as kinase inhibitors |
| DK2529622T3 (en) | 2006-09-22 | 2018-05-07 | Pharmacyclics Llc | INHIBITORS OF BRUTON-TYROSINKINASE |
| JP5840837B2 (ja) | 2007-03-30 | 2016-01-06 | メモリアル スローン−ケタリング キャンサー センター | 養子移入ｔリンパ球における副刺激リガンドの構成性発現 |
| CA2920996A1 (en) | 2007-10-19 | 2009-04-23 | Celgene Avilomics Research, Inc. | Heteroaryl compounds and uses thereof |
| EP2433713B1 (en) | 2007-12-07 | 2017-07-26 | Miltenyi Biotec GmbH | Cell processing systems and methods |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| NZ589843A (en) | 2008-06-27 | 2012-12-21 | Avila Therapeutics Inc | Pyrimidine heteroaryl compounds and uses thereof as protein kinase inhibitors |
| WO2010025177A1 (en) | 2008-08-26 | 2010-03-04 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| WO2011017219A1 (en) | 2009-08-03 | 2011-02-10 | The Regents Of The University Of California | Imidazoquinoxalinones and anti-tumor treatment |
| US10464987B2 (en) | 2009-10-06 | 2019-11-05 | Abbvie Inc. | Human single-chain T cell receptors |
| HRP20190556T1 (hr) | 2009-11-03 | 2019-06-14 | City Of Hope | SKRAĆENI OBLIK RECEPTORA EPIDERMALNOG FAKTORA RASTA ZA (EGFRt) ODABIR TRANSDUCIRANIH T-STANICA |
| KR101580714B1 (ko) | 2010-06-03 | 2016-01-04 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 인산화효소(ｂｔｋ)의 억제제의 용도 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| MX359513B (es) | 2011-03-23 | 2018-10-01 | Hutchinson Fred Cancer Res | Metodo y composiciones para inmunoterapia celular. |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| US20130078250A1 (en) | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
| EP2776451B1 (en) | 2011-11-11 | 2018-07-18 | Fred Hutchinson Cancer Research Center | Cyclin a1-targeted t-cell immunotherapy for cancer |
| EP2814846B1 (en) | 2012-02-13 | 2020-01-08 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| CN107557334B (zh) | 2012-05-03 | 2021-06-25 | 弗雷德哈钦森癌症研究中心 | 增强亲和力的t细胞受体及其制备方法 |
| KR20250151610A (ko) | 2012-06-04 | 2025-10-21 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| IL293944A (en) * | 2012-08-20 | 2022-08-01 | Hutchinson Fred Cancer Res | Method and preparations for cellular immunotherapy |
| KR102198058B1 (ko) | 2012-10-02 | 2021-01-06 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
| CN111329989A (zh) | 2012-11-02 | 2020-06-26 | 药品循环有限责任公司 | Tec家族激酶抑制剂辅助疗法 |
| WO2014082085A1 (en) | 2012-11-26 | 2014-05-30 | The University Of North Carolina At Chapel Hill | Use of itk inhibitors for the treatment of cancer |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| WO2014097442A1 (ja) | 2012-12-20 | 2014-06-26 | 三菱電機株式会社 | 車載装置及びプログラム |
| WO2014105958A2 (en) | 2012-12-26 | 2014-07-03 | Medivation Technologies, Inc. | Fused pyrimidine compounds and use thereof |
| CN105377261B (zh) | 2013-03-15 | 2017-12-15 | 南特生物科学公司 | 取代的吲哚‑5‑酚衍生物和它们的治疗应用 |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| US8957080B2 (en) | 2013-04-09 | 2015-02-17 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
| US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
| EP3004168A4 (en) | 2013-05-24 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| PT3083671T (pt) | 2013-12-20 | 2020-12-24 | Hutchinson Fred Cancer Res | Moléculas efetoras quiméricas etiquetadas e recetores destas |
| SI3888674T1 (sl) * | 2014-04-07 | 2024-08-30 | Novartis Ag | Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19 |
| MA45341A (fr) * | 2016-06-06 | 2019-04-10 | Hutchinson Fred Cancer Res | Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive |
| JP2020511462A (ja) * | 2016-12-03 | 2020-04-16 | ジュノー セラピューティクス インコーポレイテッド | キナーゼ阻害剤との組み合わせで治療用ｔ細胞を使用するための方法および組成物 |
-
2017
- 2017-11-03 EP EP17807967.9A patent/EP3534938A2/en not_active Withdrawn
- 2017-11-03 CA CA3042049A patent/CA3042049A1/en active Pending
- 2017-11-03 WO PCT/US2017/060060 patent/WO2018085731A2/en not_active Ceased
- 2017-11-03 JP JP2019523665A patent/JP2019532997A/ja not_active Withdrawn
- 2017-11-03 MA MA046783A patent/MA46783A/fr unknown
- 2017-11-03 CN CN201780082035.6A patent/CN110139669A/zh active Pending
- 2017-11-03 US US16/346,528 patent/US20190298772A1/en not_active Abandoned
- 2017-11-03 MX MX2019005029A patent/MX2019005029A/es unknown
- 2017-11-03 AU AU2017355544A patent/AU2017355544A1/en not_active Abandoned
-
2019
- 2019-04-29 MX MX2023004707A patent/MX2023004707A/es unknown
-
2023
- 2023-06-23 JP JP2023103197A patent/JP2023120386A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019532997A5 (OSRAM) | ||
| TWI786044B (zh) | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 | |
| AU2017302668B2 (en) | Combination therapies of chimeric antigen receptors and PD-1 inhibitors | |
| JP6877147B2 (ja) | 放射線療法と併用されるｐｄ−１およびｐｄ−ｌ１に対する拮抗薬を用いたがんの治療法 | |
| JP2020518591A5 (OSRAM) | ||
| JP2022184862A (ja) | 腫瘍微小環境内の機能不全抗原特異的ｃｄ８＋ｔ細胞 | |
| JP2021501606A5 (OSRAM) | ||
| JP2020511462A5 (OSRAM) | ||
| KR20190120792A (ko) | 폐암의 치료를 위한 항-pd-1 항체 | |
| KR20230148387A (ko) | T 세포 요법을 위한 진단 방법 | |
| KR20230147769A (ko) | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 | |
| CN108602889A (zh) | 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体 | |
| JP2019536460A5 (OSRAM) | ||
| JP2024519335A (ja) | がん免疫療法のための投薬レジメン | |
| Nader et al. | Ofatumumab in rituximab-refractory autoimmune hemolytic anemia associated with chronic lymphocytic leukemia: a case report and review of literature | |
| JP2025524564A (ja) | Ｃｄ１９指向性がん免疫療法の投与レジメン | |
| JPWO2020113188A5 (OSRAM) | ||
| JPWO2020252218A5 (OSRAM) | ||
| Zhuang et al. | Efficacy and immune mechanisms of cetuximab for the treatment of metastatic colorectal cancer | |
| JP2025538424A (ja) | 併用療法の投与レジメン | |
| WO2025006631A1 (en) | Dosing regimens for treatment of cancer | |
| Sibéril | Tight Interplay Between Therapeutic Monoclonal | |
| Kato | Therapeutic Monoclonal Antibodies for Cancer: The Past, Present, and Future | |
| CN121038798A (zh) | Cd4+细胞毒性t细胞及其使用方法 | |
| RU2019144333A (ru) | Изделия и способы для лечения с использованием адоптивной клеточной терапии |